Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Tocilizumab drip preferable to jab for managing COVID-19-related cytokine storm

22 Oct 2020

In the treatment of cytokine storm syndrome due to the coronavirus disease (COVID-19), administering tocilizumab via the intravenous (IV) route appears to be more effective than subcutaneous (SC) therapy, leading to earlier symptom improvement and better survival, according to a study.

The retrospective analysis included 125 patients (mean age, 58 years; 33.6 percent), 65 of which received IV and 60 received SC therapy. Overall, 82 patients required supplemental oxygen and/or considered to have severe disease while 43 were on mechanical ventilation and considered to have critical illness.

Prior to treatment initiation, cytokine release syndrome criteria were grade 3 in 36 (55 percent) patients and grade 4 in 27 (42 percent) in the IV group, and in 32 (53 percent) and 26 (43 percent) patients, respectively, in the SC group.

At day 7, respiratory parameters improved in a greater proportion of patients in the IV group than in the SC group (52 percent vs 28 percent; p=0.01).

The respective 7- and 28-day mortality rates were 15 percent and 37 percent in the IV group and 17 percent and 50 percent in the SC group, with the difference not reaching statistical significance. However, in-hospital mortality rate was markedly lower in the IV group (38 percent vs 57 percent; p=0.04).

Corticosteroids were administered in >90 percent of patients in each group, but more patients in the IV group received convalescent plasma.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

5 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 4 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.